Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock Portfolio News / By Karina Tin July 8, 2020 Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock Read More »
Arcus Biosciences Appoints Bob Goeltz as Chief Financial Officer Portfolio News / By Karina Tin July 7, 2020 Arcus Biosciences Appoints Bob Goeltz as Chief Financial Officer Read More »
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor Portfolio News / By Karina Tin June 22, 2020 Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor Read More »
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials Portfolio News / By Karina Tin June 19, 2020 Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials Read More »
Rapt Therapeutics Appoints Peter Svennilson to Board of Directors Portfolio News / By Karina Tin June 18, 2020 Rapt Therapeutics Appoints Peter Svennilson to Board of Directors Read More »
Revolution Medicines Appoints Peter Svennilson to its Board of Directors Portfolio News / By Karina Tin June 18, 2020 Revolution Medicines Appoints Peter Svennilson to its Board of Directors Read More »
Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team Portfolio News / By Karina Tin June 16, 2020 Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team Read More »
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock Portfolio News / By Karina Tin June 16, 2020 Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock Read More »
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise Portfolio News / By Karina Tin June 12, 2020 Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise Read More »
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 Portfolio News / By Karina Tin June 9, 2020 Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 Read More »
